Edwards Lifesciences Corporation (NYSE:EW) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund lowered its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 4.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 789,677 shares of the medical research company's stock after selling 36,800 shares during the period. New York State Common Retirement Fund owned 0.13% of Edwards Lifesciences worth $57,236,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Allspring Global Investments Holdings LLC lifted its stake in shares of Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after acquiring an additional 145 shares during the period. Alyeska Investment Group L.P. acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth $49,038,000. Dynamic Advisor Solutions LLC lifted its stake in shares of Edwards Lifesciences by 2.4% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after acquiring an additional 370 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Edwards Lifesciences by 13.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after acquiring an additional 9,188 shares during the period. Finally, Simplify Asset Management Inc. acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth $5,979,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Analysts Set New Price Targets

EW has been the subject of a number of research analyst reports. Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. Truist Financial cut their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a report on Friday, April 11th. Citigroup reiterated a "buy" rating and issued a $95.00 price target (up previously from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Robert W. Baird increased their price target on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a report on Thursday, April 24th. Finally, Evercore ISI increased their price target on shares of Edwards Lifesciences from $73.00 to $77.00 and gave the company an "in-line" rating in a report on Tuesday, July 8th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of "Hold" and a consensus target price of $80.40.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $78.07 on Monday. The company has a market cap of $45.79 billion, a PE ratio of 11.15, a price-to-earnings-growth ratio of 3.92 and a beta of 1.11. Edwards Lifesciences Corporation has a 12 month low of $58.93 and a 12 month high of $91.49. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.45 and a quick ratio of 3.66. The company has a 50-day simple moving average of $76.30 and a 200-day simple moving average of $73.35.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The business had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The company's quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.66 earnings per share. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $75.23, for a total transaction of $673,308.50. Following the transaction, the insider directly owned 206,900 shares of the company's stock, valued at $15,565,087. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total transaction of $198,918.00. Following the transaction, the vice president directly owned 50,356 shares in the company, valued at approximately $3,897,554.40. This trade represents a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,848 shares of company stock worth $2,314,488. Corporate insiders own 0.34% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.